Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori
Gut and Liver
; : 452-456, 2012.
Article
de En
| WPRIM
| ID: wpr-58003
Bibliothèque responsable:
WPRO
ABSTRACT
BACKGROUND/AIMS: This study assessed the efficacy of a rifaximin plus levofloxacin-based rescue regimen in patients that had failed both triple and quadruple standard regimens for the eradication of Helicobacter pylori. METHODS: We treated patients for H. pylori between August 2009 and April 2011. The triple regimen consisted of combined treatment with amoxicillin, clarithromycin, and pantoprazole for 1 week. For failed cases, a quadruple regimen of tetracycline, metronidazole, bismuth dicitrate, and lansoprazole for 1 week was administered. The rescue regimen for persistently refractory cases was rifaximin 200 mg t.i.d., levofloxacin 500 mg q.d., and lansoprazole 15 mg b.i.d. for 1 week. RESULTS: In total, 482 patients were enrolled in this study. The eradication rates associated with the first and second regimens were 58% and 60%, respectively. Forty-seven out of 58 patients who failed with the second-line regimen received rifaximin plus levofloxacin-based third-line therapy. The eradication rate for the third regimen was 65%. The cumulative eradication rates were 58%, 85%, and 96% for each regimen, respectively. CONCLUSIONS: A rifaximin plus levofloxacin-based regimen could be an alternative rescue therapy in patients with resistance to both triple and quadruple regimens for the eradication of H. pylori.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Rifamycine
/
Tétracycline
/
Bismuth
/
Ofloxacine
/
Helicobacter pylori
/
Helicobacter
/
Clarithromycine
/
(Pyridin-2-ylméthyl)sulfinyl-1H-benzimidazoles
/
Amoxicilline
/
Métronidazole
Limites du sujet:
Humans
langue:
En
Texte intégral:
Gut and Liver
Année:
2012
Type:
Article